Clinical trial
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by…
NCT00322803 · elbion AG, Industry · Terminated
Key facts
| NCT number | NCT00322803 |
|---|---|
| Title | ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment |
| Official title | International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose… |
| Lead sponsor | elbion AG, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Panic Disorder |
| Intervention type | Drug |
| Interventions | ELB139 |
| Enrollment | 24 |
| Start date | May 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | May 8, 2006 |
| Last update posted | Sep 29, 2006 |
| Countries | Germany, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: